Shots:

• The approval is based on a pivotal study- DREAMM-2 assessing Blenrep (2.5 mg/kg- q3w) in 218 patients with relapsed or refractory multiple myeloma who had actively progressing disease that had worsened despite current SoC
• Results: Blenrep demonstrated an ORR (31%)- DoR not reached at the 6-mos. analysis- but 73% of responders had a DoR ≥ 6 mos. Continued approval for this indication depends upon verification and description of clinical benefit in confirmatory trials
• Blenrep (belantamab mafodotin-blmf) is an antibody drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F. Blenrep is the 1st anti-BCMA therapy approved globally and 5th major medicine approval for GSK in 2020

­ Ref: Twitter | Image: GSK